NYSE: MANE · Life Sciences · 6 alerts · CIK 1827635
Share price
$128.05Close, Nov 16
Market cap
$5.4B
Shares outstanding
42.2MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Veradermics, Inc filings on SEC EDGAR ↗
Veradermics Director Patrick G. Enright Sells $75.2M of Stock
Patrick G. Enright, Director, sold 500,000 shares of Veradermics, Inc at $150.38 a share, worth $75.2M in total on Nov 11, 2026. Shares held after the trade: 1,803,474 (-12.2%).
Veradermics 10% Owner Longitude Capital Partners V LLC Sells $75.2M of Stock
Longitude Capital Partners V LLC, 10% Owner, sold 500,000 shares of Veradermics, Inc at $150.38 a share, worth $75.2M in total on Nov 11, 2026. Shares held after the trade: 1,803,474 (-12.2%).
Veradermics, Inc. is a clinical-stage biopharmaceutical company focused on developing VDPHL01 for pattern hair loss. As of November 5, 2026, the company had 42,195,472 shares of common stock outstanding and continues to incur substantial losses with no products yet approved for commercial sale.
Veradermics reported Q3 2026 financial results and highlighted clinical progress for its lead candidate VDPHL01, which recently achieved positive Phase 3 and Phase 2/3 results in male pattern hair loss. The company ended the quarter with $798.4 million in cash, which is expected to fund operations into 2030 through potential commercial launch.
“This has been a defining year for Veradermics as we advanced the development of VDPHL01 as a potential treatment for pattern hair loss in both men and women. In men, we reported topline results from two positive registration-directed trials, Studies ‘302’ and ‘304’, which collectively enrolled more than 1,000 male participants and demonstrated early, consistent, and robust hair growth.”
Reid Waldman, M.D., Chief Executive Officer of Veradermics
“These accomplishments bring us closer to addressing a significant unmet need in pattern hair loss for both men and women. We remain well capitalized to continue the development of VDPHL01 and advance preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approved, as a foundational treatment for pattern hair loss.”
Reid Waldman, M.D., Chief Executive Officer of Veradermics
Veradermics announced positive 12-month topline results from Part B of its Phase 2/3 Study '302' evaluating VDPHL01 for male pattern hair loss. The data showed significant increases in non-vellus hair counts and high rates of patient-reported visible improvement with no new safety signals. These results support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss in nearly 30 years.
Veradermics announced positive topline results from its Phase 3 '304' clinical trial of VDPHL01 for male pattern hair loss, meeting all primary and secondary endpoints with high statistical significance. The study demonstrated robust increases in hair count and rapid onset of activity as early as Month 2, with a favorable safety profile and no treatment-related serious adverse events. These results, combined with prior Phase 2/3 data, support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss.